Ticagrelor Monotherapy after 3 Months: Is the Current Strategy Worth Changing?

Dual antiplatelet therapy (DAPT) after PCI with DES has shown noticeable reduction of thrombotic events, especially in acute coronary syndromes (ACS). However, this therapy encompasses increased bleeding, especially in elderly patients increasingly undergoing percutaneous intervention. Even though most bleeding events might not be fatal (many of them are mostly digestive) they do involve higher hospitalization rate and therefore higher health cost. 

Research on the use of short term DAPT is not new, and outcomes so far have been promising; however, its indication in ACS patients remains unclear. 

The present prespecified analysis of the randomized TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention) compares patients with and without prior acute myocardial infarction (AMI), with special attention to evolution with 12 month DAPT vs 3 month DAPT followed by ticagrelor monotherapy + placebo at 12 months. 

6532 patients were randomized: 4595 without prior AMI (70.3%) and 1937 with prior AMI (29,7%).

There were no significant differences between the populations, except for smoking and multivessel disease in patients receiving ticagrelor + aspirin among patients with no prior MI. Among the patients with prior MI there was a higher proportion of insulin dependent diabetes, dyslipidemia, hypertension, multivessel disease, PCI and CABG. 

At one-year followup, global bleeding rate was similar between patients with and without prior AMI (5% vs. 5.5% respectively). However, looking at patients who had received ticagrelor + placebo, the group with prior MI presented less bleeding when compared against patients with no prior MI (3.4% vs. 6.7%; HR: 0.50; 95% CI: 0.33-0.76 and 4.2% vs 7.0%; HR: 0.58; 95% CI:0.45-0.76 respectively). 

Read also: Low Risk Patients: TAVR with Self-Expanding Valves Offers Similar Outcomes to Surgery Based on a Bayesian Analysis?

The presence of death, AMI or stroke was higher in patients with prior AMI (5.7% vs 3.2%; P < 0.001).

There were no differences in cardiac death, non-fatal infarction, non-fatal stroke, BARC bleeding 2.3 or 5, definite or probable thrombosis.

Conclusion

Ticagrelor monotherapy is associated with a significant reduction of bleeding events compared against ticagrelor + aspirin, with no compromise of ischemic prevention among high-risk patients with a history of MI undergoing PCI. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board, SOLACI.org

Original Title: Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI. A Prespecified TWILIGHT Substudy.

Reference: Mauro Chiarito, et al. J Am Coll Cardiol Intv 2022;15:282–293.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....